colchicine has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, A; Gao, S; Ge, Y; Hao, J; Huang, C; Li, H; Liu, J; Sun, H; Wang, X; Wang, Y; Wu, L; Xu, C; Yuan, Y; Zhao, T | 1 |
1 other study(ies) available for colchicine and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Carrier Proteins; Cell Line, Tumor; Colchicine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; LIM Domain Proteins; Mice; Neoplasm Proteins; NF-kappa B; Nucleosomes; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |